ReviewDrugs2006
Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia.
Review in Drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 38 citations in OpenAlex.
- Lowering serum urate does not improve endothelial function in patients with type 2 diabetes.Diabetologia · 2007Trial
- Centromeric Sequences in Ogataea polymorpha Genome Enable Development of Stable Multigene Expression Plasmid Tools.Microbial biotechnology · 2025Article
- A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China.Journal of clinical laboratory analysis · 2023Article
- Microreactor equipped with naturally acid-resistant histidine ammonia lyase from an extremophile.Materials advances · 2022Article
- Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.BMJ case reports · 2021Article
- Uric acid in plants and microorganisms: Biological applications and genetics - A review.Journal of advanced research · 2017Review
- Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.Molecular and clinical oncology · 2017Article
- Tumor lysis syndrome in the emergency department: challenges and solutions.Open access emergency medicine : OAEM · 2015Review
- PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.Pharmacogenetics and genomics · 2014Review
- PharmGKB summary: methylene blue pathway.Pharmacogenetics and genomics · 2013Article
- The epidemiology and treatment of gout.Open access rheumatology : research and reviews · 2011Review
- Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.International journal of medical sciences · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous rasburicase (Elitek, Fasturtec) is the first recombinant uricolytic agent. It is indicated for the management of anticancer therapy-induced hyperuricaemia in paediatric patients in the EU and US, and in adult patients in the EU. Rasburicase is effective and generally well tolerated in adult and paediatric patients with, or at risk of developing, anticancer therapy-induced hyperuricaemia. It is associated with potentially serious haematological adverse events and hypersensitivity reactions, which must be considered prior to and during administration; rasburicase is contraindicated in patients predisposed to haemolysis or methaemoglobinaemia and in patients with glucose-6-phosphate dehydrogenase deficiency. Unlike allopurinol, rasburicase acts on existing uric acid concentrations. Rasburicase treatment resulted in significantly less systemic exposure to uric acid and a quicker therapeutic response than allopurinol in paediatric patients; further studies are needed to determine the comparative efficacy and tolerability of rasburicase versus allopurinol in adult patients. Although further pharmacoeconomic data would be useful, rasburicase was most cost effective for the prevention of hyperuricaemia in children and for treatment of this condition in adults. Thus, rasburicase is a useful option for the prophylaxis or treatment of anticancer therapy-induced hyperuricaemia in both adult and paediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.